In short
This article discusses clinical trials investigating the use of (+)-α-dihydrotetrabenazine, also known as (2R,3R,11Br)-1,3,4,6,7,11B-Hexahydro-9,10-Dimethoxy-3-(2-Methylpropyl)-2H-Benzo[A]Quinolizin-2-Ol, for the treatment of moderate to severe tardive dyskinesia. These trials aim to evaluate the safety, tolerability, and efficacy of this drug in reducing abnormal involuntary movements associated with tardive dyskinesia. The studies include both open-label and randomized, double-blind, placebo-controlled designs to thoroughly assess the drug's potential as a long-term treatment option for patients with this challenging condition.
At a glance
- Drug Name
- (+)-α-dihydrotetrabenazine (ADE513)
- Chemical Name
- (2R,3R,11Br)-1,3,4,6,7,11B-Hexahydro-9,10-Dimethoxy-3-(2-Methylpropyl)-2H-Benzo[A]Quinolizin-2-Ol
- Condition Studied
- Moderate to severe tardive dyskinesia
- Study Designs
- Open-label and randomized, double-blind, placebo-controlled
- Primary Endpoint
- Change in AIMS score from baseline to Week 12
- Key Secondary Endpoints
- Safety, tolerability, CGIC and PGIC scores
- Dosage Form
- Oral solution
- Maximum Daily Dose
- 25 mg
- Treatment Duration
- Up to 54 weeks
- Key Inclusion Criteria
- Adults 18-75 years, TD diagnosis, stable psychiatric condition
- Key Exclusion Criteria
- Recent use of certain medications, significant cardiac or liver abnormalities, active substance abuse
Introduction
A new medication is being studied for the treatment of tardive dyskinesia, a condition characterized by involuntary, repetitive body movements. This article will provide information about the drug, its potential benefits, and ongoing clinical trials.
What is Tardive Dyskinesia?
Tardive dyskinesia is a neurological disorder that causes involuntary, repetitive body movements. These movements often affect the face, tongue, and limbs. The condition is usually a side effect of long-term use of certain medications, particularly antipsychotic drugs used to treat mental health conditions.
About the Medication
The medication being studied is called (2R,3R,11BR)-1,3,4,6,7,11B-HEXAHYDRO-9,10-DIMETHOXY-3-(2-METHYLPROPYL)-2H-BENZO[A]QUINOLIZIN-2-OL. It's a mouthful, so it's also known by several other names:
- (+)-α-Dihydrotetrabenazine
- (+)-α-DHTBZ
- (+)-DTBZ
- NBI-98782
- ADE513 (sponsor product code)
This medication is being developed as an oral solution, which means it's a liquid that you drink.
How It Works
The medication is classified as a VMAT2 inhibitor. VMAT2 stands for Vesicular Monoamine Transporter 2. This protein is responsible for packaging and transporting certain chemicals (neurotransmitters) in the brain. By inhibiting VMAT2, the medication aims to reduce the abnormal movements associated with tardive dyskinesia.
Clinical Trials
The medication is currently being studied in clinical trials to evaluate its safety and effectiveness. Two main studies are underway:
- An open-label safety study for patients with moderate to severe tardive dyskinesia. This study aims to evaluate the safety and tolerability of long-term maintenance therapy with the medication.
- A study with two parts: an open-label part followed by a randomized, double-blind, placebo-controlled part. This study aims to evaluate the efficacy of the medication in reducing abnormal involuntary movements of tardive dyskinesia.
Potential Benefits
The main goal of this medication is to reduce the abnormal involuntary movements associated with tardive dyskinesia. Researchers are measuring this using a scale called the Abnormal Involuntary Movement Scale (AIMS). They're looking to see if the medication can:
- Reduce the AIMS score, indicating a decrease in abnormal movements
- Improve the overall condition as assessed by doctors (Clinical Global Impression of Change - CGIC)
- Improve the condition as perceived by patients themselves (Patient Global Impression of Change - PGIC)
If successful, this medication could significantly improve the quality of life for people living with tardive dyskinesia.
Safety and Side Effects
As with any medication, safety is a crucial concern. The clinical trials are closely monitoring for any adverse effects. Some areas of focus include:
- Changes in heart rhythm (monitored through ECG)
- Liver function (monitored through blood tests)
- Mental health status (monitored through scales like the Hospital Anxiety and Depression Scale)
- Any other unexpected side effects
It's important to note that the full safety profile of this medication is still being determined through these clinical trials.
Who Can Take This Medication?
The medication is being studied in adults aged 18-75 with moderate to severe tardive dyskinesia. However, there are several factors that determine eligibility for the clinical trials. Some key points include:
- Participants must have a clinical diagnosis of tardive dyskinesia
- They must be in stable psychiatric condition
- Certain medical conditions or medications may exclude participation
- Pregnant or breastfeeding women are not eligible
It's important to note that this medication is still in the testing phase and is not yet available for general use. If you think you might be eligible for one of the clinical trials, you should discuss this with your healthcare provider.